Brief: Axcella Announces Positive Interim Data From Phase 2B Emmpact Study Of AXA1125 In NASH
29/09/2022 11:14
Sept 29 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B
EMMPACT
STUDY OF AXA1125 IN NONALCOHOLIC STEATOHEPATITIS (NASH)
* AXCELLA HEALTH INC - AXA1125 CONTINUES TO DEMONSTRATE A
SAFE AND
WELL TOLERATED PROFILE
Source text for Eikon: ID:nBw7Y8q3ta
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment